As per the current market research conducted by the CMI Team, the global Lung Cancer Screening Software Market size is expected to record a CAGR of 19.6% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 2.8 Billion. By 2033, the valuation is anticipated to reach USD 23.3 Billion.

Lung Cancer Screening Software Market: Growth Factors and Dynamics

  • Advancements in Imaging Technology: Continuous improvements in imaging technologies, such as high-resolution CT scans and AI-enhanced imaging, contribute to enhanced precision in lung cancer screening software, improving diagnostic accuracy.
  • Technological Innovations in AI: Ongoing advancements in artificial intelligence (AI) algorithms enable lung cancer screening software to analyze complex imaging data swiftly and accurately, enhancing diagnostic capabilities.
  • Integration of Machine Learning: Machine learning integration allows the software to learn and adapt, improving its ability to identify patterns and anomalies in lung scans for more effective screening.
  • Government Initiatives for Cancer Screening: Supportive governmental policies, awareness campaigns, and funding for cancer screening programs contribute to the growth of the lung cancer screening software market.
  • Focus on Early Detection: Healthcare professionals and institutions increasingly emphasize early detection of lung cancer, driving the demand for advanced screening solutions and boosting market growth.
  • Patient-Centric Approaches: The development of user-friendly interfaces and patient-centric features in screening software enhances the patient experience, increasing acceptance and adoption of these technologies.
  • Collaborations with Healthcare Providers: Partnerships and collaborations between software developers and healthcare institutions facilitate the integration of screening solutions into existing healthcare systems, driving market expansion.
  • Data-driven Decision-making: The use of data analytics in lung cancer screening software allows healthcare providers to make informed decisions, improving overall efficiency and patient outcomes.
  • Emphasis on Preventive Healthcare: Growing awareness of the importance of preventive healthcare measures, including regular lung cancer screenings, fuels the demand for screening software.
  • Global Aging Population: The increasing global aging population contributes to a higher incidence of lung cancer, creating a sustained demand for advanced screening technologies.
  • Advancements in Personalized Medicine: Integration of personalized medicine approaches in lung cancer screening software enables tailored and targeted interventions, fostering market growth as healthcare becomes more individualized.

Lung Cancer Screening Software Market: Partnership and Acquisitions

  • On October 9, 2023, DELFI Diagnostics introduced FirstLook Lung, a blood test boasting a 99.7% negative predictive value (NPV) for detecting lung cancer through low-dose CT. The test provides convenient, accurate, and personalized results, revolutionizing cancer detection.
  • In August 2023, the LUNGevity Foundation launched the Early Lung Cancer Center (ELCC) to expedite the development and widespread adoption of early detection and treatment options. The initiative aims to improve long-term survival and enhance the quality of life for individuals diagnosed with lung cancer.
  • In May 2022, DELFI Diagnostics initiated the CASCADE-LUNG study, enrolling participants for its liquid biopsy test, designed for early lung cancer detection during low-dose CT screening. The prospective, multi-center trial aims to clinically validate DELFI’s liquid biopsy test.
  • In January 2020, Amgen Inc. announced strategic collaborations with Guardant Health, Inc. and QIAGEN N.V. for companion diagnostics (CDx) development for investigational cancer treatment AMG 510. Focused on non-small cell lung cancer (NSCLC), these agreements leverage blood and tissue-based CDx tests for AMG 510, the first KRASG12C inhibitor advancing for investigation in treating multiple tumor types. KRAS G12C is a frequently mutated oncogene in human cancer.

Report Scope

Feature of the ReportDetails
Market Size in 2024USD 2.8 Billion
Projected Market Size in 2033USD 23.3 Billion
Market Size in 2023USD 2.4 Billion
CAGR Growth Rate19.6% CAGR
Base Year2023
Forecast Period2024-2033
Key SegmentBy Mode of Delivery, Product, Type, Application, Platform, Purchase Mode, End User, Distribution Channel and Region
Report CoverageRevenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional ScopeNorth America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying OptionsRequest tailored purchasing options to fulfil your requirements for research.

Lung Cancer Screening Software Market: COVID-19 Analysis

The COVID-19 pandemic has significantly impacted the lung cancer screening software market, influencing both challenges and opportunities:

  • Disruption in Screening Programs: Lockdowns and restrictions during the pandemic disrupted regular healthcare services, including lung cancer screening programs, leading to delays and cancellations.
  • Resource Diversion: Healthcare resources were diverted towards managing the surge in COVID-19 cases, impacting the prioritization and allocation of resources for lung cancer screening initiatives.
  • Supply Chain Disruptions: The pandemic disrupted global supply chains, affecting the production and distribution of medical equipment, and potentially delaying the adoption of new screening technologies.
  • Telemedicine and Remote Monitoring: The emphasis on telemedicine and remote healthcare monitoring during the pandemic has opened opportunities for the integration of lung cancer screening software into virtual healthcare platforms.
  • Increased Awareness: The pandemic has heightened awareness about healthcare and the importance of early detection, potentially leading to a renewed emphasis on lung cancer screening programs.
  • Accelerated Digital Transformation: The need for remote healthcare solutions has accelerated digital transformation in the healthcare sector, creating a conducive environment for the adoption of advanced screening technologies.
  • Research and Development Focus: The global health crisis has spurred research and development efforts, potentially leading to innovations and improvements in lung cancer screening software.
  • Government Support: Governments and healthcare organizations may recognize the importance of preventive healthcare, prompting increased support and funding for lung cancer screening initiatives post-pandemic.
  • Remote Patient Monitoring: The shift towards remote patient monitoring may drive the integration of lung cancer screening software into home-based healthcare solutions, enhancing accessibility and early detection.

While the immediate impact of COVID-19 posed challenges, the evolving landscape may offer opportunities for innovation and adaptation in the lung cancer screening software market as healthcare systems worldwide continue to respond and recover.

Global Lung Cancer Screening Software Market 2024–2033 (By Billion)

www.custommarketinsight.com

List of the prominent players in the Lung Cancer Screening Software Market:

  • Siemens Healthineers
  • Philips Healthcare
  • GE Healthcare
  • IBM Watson Health
  • McKesson Corporation
  • Koninklijke Philips N.V.
  • Varian Medical Systems
  • MIM Software Inc.
  • Eon Health
  • Thermo Fisher Scientific
  • Hologic Inc.
  • MeVis Medical Solutions AG
  • Aidence
  • Inspirata Inc.
  • Optellum
  • Others

The Lung Cancer Screening Software Market is segmented as follows:

By Mode of Delivery

  • Cloud Based Solutions
  • On-Premise Solutions
  • Web Based Solutions

By Product

  • Lung Cancer Screening Radiology Solution
  • Lung Cancer Screening Patient Management Software
  • Nodule Management Software
  • Data Collection and Reporting
  • Patient Coordination and Workflow
  • Lung Nodule Computer Aided Detection
  • Pathology and Cancer Staging
  • Statistical Audit Reporting
  • Screening PACS
  • Practice Management
  • Audit Log Tracking

By Type

  • Computer-Assisted Screening
  • Traditional Screening

By Application

  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)

By Platform

  • Standalone
  • Integrated

By Purchase Mode

  • Institutional
  • Individual

By End User

  • Oncology Centers
  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Distribution Channel

  • Direct Tender
  • Third Party Distributors

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America